Baxter International Looks At Reducing Hospital Infection Rates In China
This article was originally published in PharmAsia News
Baxter International recently hosted a forum in Beijing, where Baxter's Chief Scientific Officer Norbert Riedel and local experts shared their experiences on how to reduce hospital infections, which affect 10 percent of hospitalized patients in China. Riedel revealed that the company has looked into drug application safety issues and various methods of controlling hospital infections. These cover the procedure and management of intravenous infusions, including Baxter's closed drug dispensing system, premixed drugs, intravenous infusion bags and antimicrobial-coated IV connectors. Baxter has set up a premixed drug R&D center to develop products suitable for the local market. New premixed drugs are expected to be launched next year, which will elevate China's level of research and application in the field. (Click here for more - Chinese Language)
You may also be interested in...
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.